In this May 2020 picture offered by Eli Lilly, researchers put together mammalian cells to supply doable COVID-19 antibodies for testing in a laboratory in Indianapolis.
David Morrison | Eli Lilly by way of AP
LONDON — Eli Lilly introduced on Wednesday it had discovered proof of idea information from an interim evaluation of the BLAZE-1 scientific trial that confirmed a reduced rate of hospitalization for coronavirus patients handled with its neutralizing antibody drug.
“These interim data from the BLAZE-1 trial suggest that LY-CoV555, an antibody specifically directed against SARS-CoV-2, has a direct antiviral effect and may reduce COVID-related hospitalizations,” Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories, stated in a assertion.
“The results reinforce our conviction that neutralizing antibodies can help in the fight against COVID-19,” Skovronsky stated.